| pubmed-article:8392941 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8392941 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:8392941 | lifeskim:mentions | umls-concept:C0206529 | lld:lifeskim |
| pubmed-article:8392941 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:8392941 | lifeskim:mentions | umls-concept:C0210574 | lld:lifeskim |
| pubmed-article:8392941 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8392941 | pubmed:dateCreated | 1993-8-26 | lld:pubmed |
| pubmed-article:8392941 | pubmed:abstractText | The pharmacology of (DL)-4-carboxy-3-hydroxyphenylglycine was examined in baby hamster kidney cells which stably express the type I metabotropic glutamate receptor (mGluR1 alpha). DL-4-Carboxy-3-hydroxyphenylglycine dose-dependently inhibited glutamate-stimulated phosphoinositide hydrolysis in a competitive manner with a KB of 29 microM as estimated from Schild-plot analysis. The present report is the first demonstration of a potent and competitive antagonist of the mGluR1 alpha subtype. | lld:pubmed |
| pubmed-article:8392941 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8392941 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8392941 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8392941 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8392941 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8392941 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8392941 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8392941 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8392941 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8392941 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8392941 | pubmed:month | May | lld:pubmed |
| pubmed-article:8392941 | pubmed:issn | 0014-2999 | lld:pubmed |
| pubmed-article:8392941 | pubmed:author | pubmed-author:ThomsenCC | lld:pubmed |
| pubmed-article:8392941 | pubmed:author | pubmed-author:SuzdakP DPD | lld:pubmed |
| pubmed-article:8392941 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8392941 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:8392941 | pubmed:volume | 245 | lld:pubmed |
| pubmed-article:8392941 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8392941 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8392941 | pubmed:pagination | 299-301 | lld:pubmed |
| pubmed-article:8392941 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:8392941 | pubmed:meshHeading | pubmed-meshheading:8392941-... | lld:pubmed |
| pubmed-article:8392941 | pubmed:meshHeading | pubmed-meshheading:8392941-... | lld:pubmed |
| pubmed-article:8392941 | pubmed:meshHeading | pubmed-meshheading:8392941-... | lld:pubmed |
| pubmed-article:8392941 | pubmed:meshHeading | pubmed-meshheading:8392941-... | lld:pubmed |
| pubmed-article:8392941 | pubmed:meshHeading | pubmed-meshheading:8392941-... | lld:pubmed |
| pubmed-article:8392941 | pubmed:meshHeading | pubmed-meshheading:8392941-... | lld:pubmed |
| pubmed-article:8392941 | pubmed:meshHeading | pubmed-meshheading:8392941-... | lld:pubmed |
| pubmed-article:8392941 | pubmed:meshHeading | pubmed-meshheading:8392941-... | lld:pubmed |
| pubmed-article:8392941 | pubmed:meshHeading | pubmed-meshheading:8392941-... | lld:pubmed |
| pubmed-article:8392941 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8392941 | pubmed:articleTitle | 4-Carboxy-3-hydroxyphenylglycine, an antagonist at type I metabotropic glutamate receptors. | lld:pubmed |
| pubmed-article:8392941 | pubmed:affiliation | Department of Receptor Neurochemistry, Novo Nordisk A/S, Måløv, Denmark. | lld:pubmed |
| pubmed-article:8392941 | pubmed:publicationType | Journal Article | lld:pubmed |
